AU2013272701B2 - Imidazo[1,2-b]pyridazine derivatives as kinase inhibitors - Google Patents

Imidazo[1,2-b]pyridazine derivatives as kinase inhibitors Download PDF

Info

Publication number
AU2013272701B2
AU2013272701B2 AU2013272701A AU2013272701A AU2013272701B2 AU 2013272701 B2 AU2013272701 B2 AU 2013272701B2 AU 2013272701 A AU2013272701 A AU 2013272701A AU 2013272701 A AU2013272701 A AU 2013272701A AU 2013272701 B2 AU2013272701 B2 AU 2013272701B2
Authority
AU
Australia
Prior art keywords
group
imidazo
phenyl
pyridazin
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013272701A
Other languages
English (en)
Other versions
AU2013272701A1 (en
AU2013272701A2 (en
Inventor
Yoshito HAMADA
Yoshiko Kagoshima
Masaki Kiga
Yasuyuki Takeda
Ryoichi Tanaka
Yuichi Tominaga
Yuko Yamamoto
Kenji Yoshikawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daiichi Sankyo Co Ltd
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of AU2013272701A1 publication Critical patent/AU2013272701A1/en
Publication of AU2013272701A2 publication Critical patent/AU2013272701A2/en
Application granted granted Critical
Publication of AU2013272701B2 publication Critical patent/AU2013272701B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/5025Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2013272701A 2012-06-04 2013-06-03 Imidazo[1,2-b]pyridazine derivatives as kinase inhibitors Active AU2013272701B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2012-127079 2012-06-04
JP2012127079 2012-06-04
PCT/JP2013/065328 WO2013183578A1 (ja) 2012-06-04 2013-06-03 キナーゼ阻害剤としてのイミダゾ[1,2-b]ピリダジン誘導体

Publications (3)

Publication Number Publication Date
AU2013272701A1 AU2013272701A1 (en) 2015-01-15
AU2013272701A2 AU2013272701A2 (en) 2015-01-22
AU2013272701B2 true AU2013272701B2 (en) 2017-12-21

Family

ID=49711970

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013272701A Active AU2013272701B2 (en) 2012-06-04 2013-06-03 Imidazo[1,2-b]pyridazine derivatives as kinase inhibitors

Country Status (32)

Country Link
US (2) US9187489B2 (enExample)
EP (1) EP2857404B1 (enExample)
JP (1) JP5814467B2 (enExample)
KR (1) KR101781255B1 (enExample)
CN (1) CN104520300B (enExample)
AU (1) AU2013272701B2 (enExample)
BR (1) BR112014029851B1 (enExample)
CA (1) CA2874819C (enExample)
CO (1) CO7160119A2 (enExample)
CY (1) CY1119607T1 (enExample)
DK (1) DK2857404T3 (enExample)
ES (1) ES2648228T3 (enExample)
HR (1) HRP20171724T1 (enExample)
HU (1) HUE037221T2 (enExample)
IL (1) IL236075A (enExample)
IN (1) IN2014MN02497A (enExample)
LT (1) LT2857404T (enExample)
MX (1) MX357021B (enExample)
MY (1) MY170326A (enExample)
NO (1) NO2857404T3 (enExample)
NZ (1) NZ702574A (enExample)
PH (1) PH12014502721A1 (enExample)
PL (1) PL2857404T3 (enExample)
PT (1) PT2857404T (enExample)
RS (1) RS56625B1 (enExample)
RU (1) RU2635917C2 (enExample)
SG (1) SG11201408052WA (enExample)
SI (1) SI2857404T1 (enExample)
SM (1) SMT201700539T1 (enExample)
TW (1) TWI585088B (enExample)
WO (1) WO2013183578A1 (enExample)
ZA (1) ZA201408843B (enExample)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS53350B (sr) 2008-09-22 2014-10-31 Array Biopharma, Inc. Supstituisana jedinjenja imidazo[1,2-b]piridazina kao inhibitori trk kinaze
PT2725028T (pt) 2008-10-22 2016-08-31 Array Biopharma Inc Compostos de pirazolo[1,5-]pirimidina substituídos como intermediários na síntese de inibidores de cinase trk
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
HUE044025T2 (hu) 2010-05-20 2019-09-30 Array Biopharma Inc Makrociklusos vegyületek mint TRK-kináz inhibitorok
CN104470918A (zh) 2012-05-30 2015-03-25 日本新药株式会社 芳香族杂环衍生物及医药
BR112016022105B1 (pt) 2014-03-27 2023-01-31 Janssen Pharmaceutica Nv Derivados de 4,5,6,7-tetra-hidro-pirazolo[1,5- a]pirazina substituídos e derivados de 5,6,7,8-tetrahidro-4h-pirazolo[1,5-a][1,4]diazepina como inibidores do ros1 e composição farmacêutica que os compreende
BR112016021507B1 (pt) * 2014-03-27 2022-10-18 Janssen Pharmaceutica Nv Derivados de 4,5,6,7-tetra-hidro-pirazolo[1,5-a]pirimidina substituídos e derivados de 2,3-dihidro-1himidazo[1,2-b]pirazol como inibidores do ros1 e composição farmacêutica que os compreende
BR112016024672A2 (pt) * 2014-04-25 2021-02-02 Exelixis, Inc método para o tratamento de adenocarcinoma de pulmão
FI3699181T3 (fi) 2014-11-16 2023-03-28 Array Biopharma Inc Kiteinen muoto (s)-n-(5-((r)-2-(2,5-diluorifenyyli)-pyrrolidin-1-yyli)-pyratsolo[1,5-a]pyrimidin-3-yyli)-3-hydroksipyrrolidiini-1-karboksamidivetyysulfaatista
MX2017015461A (es) 2015-06-01 2018-08-15 Loxo Oncology Inc Métodos para diagnosticar y tratar el cáncer.
MX379846B (es) 2015-06-18 2025-03-11 89Bio Ltd Derivados de 4-bencil y 4-benzoil piperidina sustituidos.
AU2016280255A1 (en) 2015-06-18 2018-02-08 Cephalon, Inc. 1, 4-substituted piperidine derivatives
PL3322706T3 (pl) 2015-07-16 2021-07-19 Array Biopharma, Inc. Podstawione związki pirazolo[1,5-a]pirydynowe jako inhibitory kinazy ret
EP3368039A1 (en) 2015-10-26 2018-09-05 The Regents of The University of Colorado, A Body Corporate Point mutations in trk inhibitor-resistant cancer and methods relating to the same
CN106854174A (zh) * 2015-12-08 2017-06-16 湖南华腾制药有限公司 一种4位取代哌啶衍生物的制备方法
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
CA3019661A1 (en) 2016-04-04 2017-10-12 Loxo Oncology, Inc. Methods of treating pediatric cancers
RS65987B1 (sr) 2016-04-04 2024-10-31 Loxo Oncology Inc Tečne formulacije (s)-n-(5-((r)-2-(2,5-difluorofenil)-pirolidin-1-il)-pirazolo[1,5-]pirimidin-3-il)-3-hidroksipirolidin-1-karboksamida
EP3800189B1 (en) 2016-05-18 2023-06-28 Loxo Oncology, Inc. Preparation of (s)-n-(5-((r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
CN107400082A (zh) * 2016-05-19 2017-11-28 湖南华腾制药有限公司 一种取代哌啶衍生物的制备方法
JOP20190077A1 (ar) 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
JOP20190072A1 (ar) * 2016-10-13 2019-04-07 Glaxosmithkline Ip Dev Ltd مشتقات 1، 3 سيكلوبوتان ثنائي الاستبدال أو آزيتيدين كمثبطات للإنزيم المخلق للبروستاجلاندين d المكون للدم
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
US11168090B2 (en) 2017-01-18 2021-11-09 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyrazines as RET kinase inhibitors
US11028091B2 (en) * 2017-03-14 2021-06-08 Daiichi Sankyo Company, Limited Method for producing 3, 6-disubstituted imidazo[1, 2-b]pyridazine derivative
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
US10180422B1 (en) 2017-08-22 2019-01-15 Scripps Health Methods of treating a neuroendocrine tumor
TWI876442B (zh) 2017-10-10 2025-03-11 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
US20190247398A1 (en) 2017-10-26 2019-08-15 Array Biopharma Inc. Formulations of a macrocyclic trk kinase inhibitor
CN109748902B (zh) * 2017-11-02 2020-11-06 杭州科巢生物科技有限公司 一种盐酸安罗替尼的制备方法
JP7041265B2 (ja) * 2017-11-29 2022-03-23 ソウル大学校産学協力団 抗-ros1抗体およびその用途
CN108129288B (zh) * 2017-12-27 2021-01-22 上海毕得医药科技股份有限公司 一种反式-3-羟基环丁基甲酸的合成方法
EP3740491A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
EP3740486A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors
CA3087578C (en) 2018-01-18 2023-08-08 Array Biopharma Inc. Substituted pyrazolo[3,4-d]pyrimidine compounds as ret kinase inhibitors
WO2019191659A1 (en) 2018-03-29 2019-10-03 Loxo Oncology, Inc. Treatment of trk-associated cancers
EP3827009A4 (en) 2018-07-24 2022-04-27 Taiho Pharmaceutical Co., Ltd. HETEROBICYCLIC COMPOUNDS TO INHIBIT SHP2 ACTIVITY
CN117281803A (zh) 2018-07-31 2023-12-26 罗索肿瘤学公司 喷雾干燥的分散体和制剂
WO2020055672A1 (en) 2018-09-10 2020-03-19 Array Biopharma Inc. Fused heterocyclic compounds as ret kinase inhibitors
EP3898626A1 (en) 2018-12-19 2021-10-27 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases
JP2022515197A (ja) 2018-12-19 2022-02-17 アレイ バイオファーマ インコーポレイテッド がんを治療するためのfgfr阻害剤としての7-((3,5-ジメトキシフェニル)アミノ)キノキサリン誘導体
CN113543852A (zh) * 2019-03-06 2021-10-22 第一三共株式会社 吡咯并吡唑衍生物
JP2022526713A (ja) 2019-03-21 2022-05-26 オンクセオ がんの処置のための、キナーゼ阻害剤と組み合わせたDbait分子
AU2020270303B2 (en) * 2019-05-08 2023-09-07 Tyk Medicines, Inc. Compound used as kinase inhibitor and application thereof
GB201911928D0 (en) 2019-08-20 2019-10-02 Otsuka Pharma Co Ltd Pharmaceutical compounds
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
TW202200589A (zh) * 2020-05-28 2022-01-01 瑞士商諾華公司 Mll1抑制劑及抗癌劑
CN114957259A (zh) * 2021-02-25 2022-08-30 南京明德新药研发有限公司 氰基取代的芳香双环类化合物及其应用
US20240309007A1 (en) * 2021-07-01 2024-09-19 Anheart Therapeutics (Hangzhou) Co., Ltd. Crystalline forms of 3-{4-[(2r)-2-aminopropoxy]phenyl}-n-[(1r)- 1-(3-fluorophenyl) ethyl]imidazo[1,2-b]pyridazin-6-amine and salts thereof
CN119546609A (zh) * 2022-05-18 2025-02-28 葆元生物医药科技(杭州)有限公司 用于制备3,6-二取代-咪唑并[1,2-b]哒嗪化合物的方法
CN114989176B (zh) * 2022-07-08 2024-08-27 深圳市新樾生物科技有限公司 咪唑并哒嗪类衍生物及其应用
CN115197115B (zh) * 2022-08-25 2024-11-08 成都金博汇康医药科技有限公司 一种手性5-氧代吡咯烷-3-甲酸的制备方法与应用
CN117659043A (zh) 2022-09-07 2024-03-08 苏州朗睿生物医药有限公司 一种大环咪唑并[1,2-b]哒嗪衍生物及其制备方法和用途
CN117659020A (zh) * 2022-09-07 2024-03-08 苏州朗睿生物医药有限公司 一种咪唑并[1,2-b]哒嗪衍生物及其制备方法和用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008058126A2 (en) * 2006-11-06 2008-05-15 Supergen, Inc. Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6399780B1 (en) 1999-08-20 2002-06-04 Cephalon, Inc. Isomeric fused pyrrolocarbazoles and isoindolones
EP1317446A1 (en) 2000-09-01 2003-06-11 Glaxo Group Limited Oxindole derivatives
WO2002020479A1 (en) 2000-09-01 2002-03-14 Glaxo Group Limited Substituted oxindole derivatives as tyrosine kinase inhibitors
JP2003231687A (ja) 2002-02-04 2003-08-19 Japan Tobacco Inc ピラゾリル縮合環化合物及びその医薬用途
MY141220A (en) 2003-11-17 2010-03-31 Astrazeneca Ab Pyrazole derivatives as inhibitors of receptor tyrosine kinases
US20090227648A1 (en) 2004-04-21 2009-09-10 Astrazeneca Ab Pyrazole derivatives useful for the treatment of cancer
WO2006070943A1 (ja) * 2004-12-28 2006-07-06 Takeda Pharmaceutical Company Limited 縮合イミダゾール化合物およびその用途
DK2383268T3 (en) 2005-02-04 2015-09-14 Astrazeneca Ab PYRAZOLYLAMINOPYRIDINDERIVATER useful as kinase inhibitors
AU2006215386B2 (en) 2005-02-16 2009-06-11 Astrazeneca Ab Chemical compounds
AU2006215394B2 (en) 2005-02-16 2009-10-08 Astrazeneca Ab Chemical compounds
US20100216798A1 (en) 2005-07-29 2010-08-26 Astellas Pharma Inc Fused heterocycles as lck inhibitors
US7776878B2 (en) * 2005-08-01 2010-08-17 Hoffmann-La Roche Inc. Heterocyclic benzylamino derivatives, their manufacture and use as pharmaceutical agents
DE102005042742A1 (de) 2005-09-02 2007-03-08 Schering Ag Substituierte Imidazo[1,2b]pyridazine als Kinase-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
DE102006029447A1 (de) 2006-06-21 2007-12-27 Bayer Schering Pharma Ag Oxo-substituierte Imidazo[1,2b]pyridazine, deren Herstellung und Verwendung als Arzneimittel
CN101522682A (zh) * 2006-10-30 2009-09-02 诺瓦提斯公司 作为抗炎剂的杂环化合物
WO2008072682A1 (ja) * 2006-12-15 2008-06-19 Daiichi Sankyo Company, Limited イミダゾ[1,2-b]ピリダジン誘導体
JP2009227599A (ja) * 2008-03-21 2009-10-08 Daiichi Sankyo Co Ltd イミダゾピリダジン誘導体
EP2300469B1 (en) 2008-05-13 2015-06-24 Novartis AG Fused nitrogen containing heterocycles and compositions thereof as kinase inhibitors
RS53350B (sr) * 2008-09-22 2014-10-31 Array Biopharma, Inc. Supstituisana jedinjenja imidazo[1,2-b]piridazina kao inhibitori trk kinaze
KR101147550B1 (ko) * 2009-10-22 2012-05-17 한국과학기술연구원 단백질 키나아제 저해활성을 가지는 2,7-치환된 티에노[3,2-d]피리미딘 화합물
JPWO2012005299A1 (ja) 2010-07-07 2013-09-05 日本新薬株式会社 Rosチロシンキナーゼ阻害剤
WO2012125667A1 (en) 2011-03-17 2012-09-20 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008058126A2 (en) * 2006-11-06 2008-05-15 Supergen, Inc. Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors

Also Published As

Publication number Publication date
ES2648228T3 (es) 2017-12-29
CA2874819C (en) 2017-06-20
DK2857404T3 (en) 2017-12-04
MY170326A (en) 2019-07-17
KR20150014942A (ko) 2015-02-09
PH12014502721B1 (en) 2015-02-02
SI2857404T1 (sl) 2017-11-30
IL236075A0 (en) 2015-02-01
HUE037221T2 (hu) 2018-08-28
TWI585088B (zh) 2017-06-01
BR112014029851A2 (pt) 2017-06-27
CN104520300A (zh) 2015-04-15
BR112014029851B1 (pt) 2023-01-03
CY1119607T1 (el) 2018-04-04
CA2874819A1 (en) 2013-12-12
MX357021B (es) 2018-06-25
EP2857404A1 (en) 2015-04-08
IL236075A (en) 2017-10-31
NO2857404T3 (enExample) 2018-01-20
US20150051190A1 (en) 2015-02-19
SG11201408052WA (en) 2015-01-29
EP2857404A4 (en) 2016-01-20
SMT201700539T1 (it) 2018-01-11
EP2857404B1 (en) 2017-08-23
US20160046639A1 (en) 2016-02-18
CN104520300B (zh) 2016-12-21
JP5814467B2 (ja) 2015-11-17
CO7160119A2 (es) 2015-01-15
PT2857404T (pt) 2017-11-23
PL2857404T3 (pl) 2018-04-30
JPWO2013183578A1 (ja) 2016-01-28
HRP20171724T1 (hr) 2018-01-12
US9187489B2 (en) 2015-11-17
AU2013272701A1 (en) 2015-01-15
US9751887B2 (en) 2017-09-05
PH12014502721A1 (en) 2015-02-02
RS56625B1 (sr) 2018-03-30
TW201400486A (zh) 2014-01-01
AU2013272701A2 (en) 2015-01-22
ZA201408843B (en) 2016-01-27
RU2014153627A (ru) 2016-08-10
NZ702574A (en) 2016-07-29
MX2014014803A (es) 2015-02-12
HK1207374A1 (en) 2016-01-29
WO2013183578A1 (ja) 2013-12-12
RU2635917C2 (ru) 2017-11-17
LT2857404T (lt) 2017-11-10
KR101781255B1 (ko) 2017-09-22
IN2014MN02497A (enExample) 2015-07-17

Similar Documents

Publication Publication Date Title
AU2013272701B2 (en) Imidazo[1,2-b]pyridazine derivatives as kinase inhibitors
JP7033764B2 (ja) Cdk阻害剤としての置換型ヘテロシクリル誘導体
KR102816365B1 (ko) 피라진 화합물 및 이의 용도
EP3168219B1 (en) Pyridone derivative having tetrahydropyranyl methyl group
WO2008081914A1 (ja) Plk1阻害剤としての新規アミノピリミジン誘導体
JP7723666B2 (ja) 環式化合物およびその使用方法
CA2856505A1 (fr) Nouveaux derives de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
KR20220028072A (ko) Bet 억제제로서의 헤테로시클릭 화합물
EA030410B1 (ru) Замещенные конденсированные гетероциклы в качестве модуляторов gpr119 для лечения диабета, ожирения, дислипидемии и связанных нарушений
JP7584623B2 (ja) キナーゼ阻害活性を有する化合物
TW202122382A (zh) 乙內醯脲衍生物
EP3694331A1 (en) Indazolyl-spiro[2.3]hexane-carbonitrile derivatives as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof
TW202220987A (zh) 經取代雜環化合物及其治療用途
EP4525875A1 (en) Macrocycles as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof
EP4141003A1 (en) Pyrazolo[1,5-a]pyridine derivative, preparation method therefor, and composition and use thereof
HK1207374B (en) Imidazo[1,2-b]pyridazine derivatives as kinase inhibitors
EP4308096A1 (en) Heteroaroyl amides as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof
HK40057478B (zh) Hpk1抑制剂及其使用方法
HK40082804A (en) Amide compounds and uses thereof

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 06 JAN 2015

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ IMIDAZO(1,2-B)PYRIDAZINE DERIVATIVES AS KINASE INHIBITORS

FGA Letters patent sealed or granted (standard patent)